Patent ID: 7811774

Claim:
A method of assessing a prognosis of a patient having a breast tumor, the method comprising steps of: obtaining a tumor sample from a patient having a breast tumor; contacting the tumor sample with a panel of antibodies that includes an antibody that binds to HTF9C and at least one antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, NDRG1, and CEACAM5, wherein each of the at least one antibodies binds to a different biomarker within the group; and assessing the patient's likely prognosis based upon a pattern of binding or lack of binding of the panel to the tumor sample, wherein across a population of patients with breast tumors, a higher level of binding of the antibody that binds to HTF9C correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence, and a higher level of binding of the at least one antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, NDRG1, and CEACAM5 correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence.